Healthcare

CytoDyn (OTC: CYDY) Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model

New preclinical data using a humanized mouse model confirms and expands on the potential use of leronlimab in treating this inflammatory syndrome, a common precursor to NASH VANCOUVER, Washington, Nov 21, 2019 — CytoDyn Inc. […]

Newsmakers

CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies

CytoDyn will file for expanded access IND for patients with pancreatic, prostate, lung, breast, liver and melanoma cancers VANCOUVER, Washington, Nov 19, 2019  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology […]

Healthcare

Hoth Therapeutics (NASDQ: HOTH) to Attend Benchmark’s 8th Annual Discovery 1×1 Conference

NEW YORK, Nov. 18, 2019  — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, […]

Healthcare

Hoth Therapeutics (NASDAQ: HOTH) Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication

NEW YORK, Nov. 14, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, […]

Healthcare

First Patient in CytoDyn’s (OTC: CYDY) Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size

Breakthrough Therapy designation filing possible if more patients show similar positive results VANCOUVER, Washington, Nov. 11, 2019  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 […]

Newsmakers

Hoth Therapeutics (NASDAQ: HOTH) Makes Donation to National Eczema Association in Sponsorship of “National Eczema Awareness Month”

NEW YORK, Oct. 14, 2019  — Hoth Therapeutics, Inc.(NASDAQ: HOTH)  a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound […]

Healthcare

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock Investor Conference presentation 9/26/2019

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock investor conference presentation 9/26/2019 Hoth Therapeutics (NASDAQ: HOTH) is targeting multi-billion dollar market opportunities, with it’s pipeline of targeted dermatological therapies for eczema, psoriasis, chronic wound disorders, […]

Healthcare

CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Clinical Trial of Leronlimab (PRO 140) for Treatment of NASH

VANCOUVER, Washington, Oct. 01, 2019– CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today FDA clearance […]

Healthcare

CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

VANCOUVER, Washington, Sept. 09, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Healthcare

Hoth Therapeutics (NASDAQ: HOTH) to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference

NEW YORK, Sept. 6, 2019  — Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, […]

CEO Interview

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Dermatological therapeutics pipeline targeting multi-billion dollar opportunities (+ near-term catalysts)

Hoth Therapeutics, Inc. (NASDAQ: HOTH) will be a featured presenter at Wall Street Reporter’s Next Super Stock Live! online investor conference on September 25, 2019.              Hoth Therapeutics, Inc. (NASDAQ: HOTH) Interview […]

Healthcare

Zylo and Hoth Therapeutics (NASDAQ: HOTH) Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus

Greenville, SC, Aug. 22, 2019 — Zylo Therapeutics, dedicated to bringing innovative topical technologies to multiple facets of medicine, has entered into a definitive partnership agreement with Hoth Therapeutics (NASDAQ: HOTH) to develop a new treatment for […]